Integra LifeSciences Holdings Corporation (IART) Stock Price & Analysis
Integra LifeSciences Holdings Corporation (IART) — MoonshotScore 68/100 (Strong band), calculated Nov 18, 2026. Price $13.25 (-2.21%), as of the Nov 20, 2026 trading session; market cap $1.03B.
Educational signal · not a buy or sell recommendation · How to read this
Integra LifeSciences Holdings Corporation · IART · NASDAQ
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments. The company operates through Codman Specialty Surgical and Tissue Technologies segments, providing solutions for neurosurgery, extremity reconstruction, and general surgery.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Integra LifeSciences Holdings (IART)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, but a strained balance sheet. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Compounding; Momentum: Rising.
- EPS beat 0 of the last 4 reports
- Altman Z 1.31 · Piotroski F 7
- ROE 1.2% · ROA 2.9% · current ratio 3.62
Holding back: balance-sheet strain
Helping: business quality, an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 66 | Strong | |
| 62 | Fair | |
| 62 | Fair | |
| 68 | Strong | |
| 68 | Strong | |
| 68 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $13.25 | |
| Change on the day | -2.21% | |
| 52-week range | $8.70 – $20.49 | |
| Market capitalisation | $1.03B | — |
| Price / earnings (trailing) | 80.75 | |
| Shares traded on the day | 826.6K |
Price & events
Other perspectives
Council score for Integra LifeSciences Holdings (IART): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Integra LifeSciences Holdings (IART), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Integra LifeSciences Holdings Corporation (IART) is listed on NASDAQ. It employs 4,427 people and is led by Stuart Essig. The market values it at $1.03B.
What do the latest results show for Integra LifeSciences Holdings (IART)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $402M | -$5M | -$0.07 (diluted) |
| Q4 FY2025 | $435M | -$2M | -$0.02 (diluted) |
| Q1 FY2026 | $392M | -$5M | -$0.06 (diluted) |
| Q2 FY2026 | $419M | $4M | $0.06 (diluted) |
What are the financial strengths and risks for Integra LifeSciences Holdings (IART)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, durable growth as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z 1.31 · Piotroski F 7. Trailing ratios: ROE 1.2% · ROA 2.9% · current ratio 3.62.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.31 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Integra LifeSciences Holdings (IART)?
Short answer · as of
The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Integra LifeSciences Holdings compare with its peers?
Short answer
Integra LifeSciences Holdings's score ranks 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $81.02 Nov 20, 2026 | $1.04B | 94 5-pillar Nov 18, 2026 | |
| $12.42 Nov 20, 2026 | $715M | 92 5-pillar Nov 18, 2026 | |
| $270.47 Nov 20, 2026 | $651B | 83 5-pillar Nov 18, 2026 | |
| $99.94 Nov 20, 2026 | $128B | 81 5-pillar Nov 18, 2026 | |
| $46.56 Nov 20, 2026 | $1.39B | 79 5-pillar Nov 18, 2026 | |
| $9.95 Nov 19, 2026 | $681M | 79 5-pillar Nov 18, 2026 | |
| $41.98 Nov 20, 2026 | $60.9B | 77 5-pillar Nov 18, 2026 | |
| Integra LifeSciences Holdings (IART) — this page | $13.25 | $1.03B | 68 |
| $18.10 Nov 20, 2026 | $769M | 62 5-pillar Nov 18, 2026 | |
| $23.73 Nov 20, 2026 | $1.07B | 39 5-pillar Nov 18, 2026 | |
| $31.74 Nov 20, 2026 | $829M | 37 5-pillar Nov 18, 2026 | |
| $18.16 Nov 20, 2026 | $886M | 34 5-pillar Nov 18, 2026 | |
| $6.12 Nov 20, 2026 | $800M | 33 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $13.00 – $25.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $16.43
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $14.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 1, 2026
- Transactions
- 5
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 0
- Other transactions
- 5
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IART in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported IART in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Integra LifeSciences Holdings (IART)?
- Integra (IART) Up 9.9% Since Last Earnings Report: Can It Continue?
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART
- Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript
- Integra LifeSciences (IART) Stock Could Be A Bargain Based On Cash Flow
Common Questions About IART
These answers are editorial: 1 of these 9 answers is drawn from the IART research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for IART?
IART carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments.
Is IART a good stock to buy?
Stock Expert AI does not rate IART buy, sell or hold. Integra LifeSciences Holdings Corporation carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the IART stock price today?
The last price recorded for Integra LifeSciences Holdings Corporation (IART), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the IART price target?
The last analyst consensus price target we captured for Integra LifeSciences Holdings Corporation (IART), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What do analysts say about IART stock?
Analyst coverage of Integra LifeSciences is mixed, reflecting the company's challenges and opportunities. Some analysts highlight the company's strong market position in neurosurgery and tissue technologies, while others express concerns about its negative profit margin and high debt levels.
What are the key factors to evaluate for IART?
Integra LifeSciences Holdings Corporation (IART) holds a MoonshotScore in the moderate range. To weigh it, start with the trailing P/E under Price & valuation on this page. Global presence across the United States, Europe, and Asia Pacific provides access to multiple markets. Not financial advice.
How frequently does IART data refresh on this page?
IART's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven IART's recent stock price performance?
Integra LifeSciences Holdings Corporation (IART) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in neurosurgery and tissue technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IART overvalued or undervalued right now?
The trailing P/E of Integra LifeSciences Holdings Corporation (IART) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com